Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes - PubMed (original) (raw)
Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes
Y Kawakami et al. J Exp Med. 1994.
Abstract
Four melanoma proteins, MART-1, gp100, tyrosinase, and tyrosinase-related protein-1 (gp75) were evaluated for recognition by HLA-A2-restricted melanoma-specific cytotoxic T lymphocytes (CTLs) derived from the tumor-infiltrating lymphocytes (TIL) of 10 different patients. 9 of 10 TIL recognized MART-1, 4 recognized gp100 (including 3 that also recognized MART-1), but none of the TIL recognized tyrosinase or gp75. Based on the known HLA-A2.1 peptide binding motifs, 23 peptides from MART-1 were synthesized in an attempt to identify the epitopes recognized by TIL. Three peptides were recognized by TIL when pulsed on T2 target cells. One of the 9-mer peptides, AAGIGILTV, was most effective in sensitizing the T2 cells for TIL lysis. This peptide was recognized by 9 of 10 HLA-A2-restricted melanoma-specific CTLs. Therefore, this peptide appears to be a very common immunogenic epitope for HLA-A2-restricted melanoma-specific TIL and may be useful for the development of immunotherapeutic strategies.
Similar articles
- Identification of new melanoma epitopes on melanosomal proteins recognized by tumor infiltrating T lymphocytes restricted by HLA-A1, -A2, and -A3 alleles.
Kawakami Y, Robbins PF, Wang X, Tupesis JP, Parkhurst MR, Kang X, Sakaguchi K, Appella E, Rosenberg SA. Kawakami Y, et al. J Immunol. 1998 Dec 15;161(12):6985-92. J Immunol. 1998. PMID: 9862734 - Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression.
Kawakami Y, Eliyahu S, Jennings C, Sakaguchi K, Kang X, Southwood S, Robbins PF, Sette A, Appella E, Rosenberg SA. Kawakami Y, et al. J Immunol. 1995 Apr 15;154(8):3961-8. J Immunol. 1995. PMID: 7706734 - Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1.
Rivoltini L, Kawakami Y, Sakaguchi K, Southwood S, Sette A, Robbins PF, Marincola FM, Salgaller ML, Yannelli JR, Appella E, et al. Rivoltini L, et al. J Immunol. 1995 Mar 1;154(5):2257-65. J Immunol. 1995. PMID: 7868898 - Immunobiology of human melanoma antigens MART-1 and gp100 and their use for immuno-gene therapy.
Kawakami Y, Rosenberg SA. Kawakami Y, et al. Int Rev Immunol. 1997;14(2-3):173-92. doi: 10.3109/08830189709116851. Int Rev Immunol. 1997. PMID: 9131386 Review. - Potential use of T cell receptor genes to modify hematopoietic stem cells for the gene therapy of cancer.
Clay TM, Custer MC, Spiess PJ, Nishimura MI. Clay TM, et al. Pathol Oncol Res. 1999;5(1):3-15. doi: 10.1053/paor.1999.0003. Pathol Oncol Res. 1999. PMID: 10079371 Review.
Cited by
- Machine learning for the identification of neoantigen-reactive CD8 + T cells in gastrointestinal cancer using single-cell sequencing.
Sun H, Han X, Du Z, Chen G, Guo T, Xie F, Gu W, Shi Z. Sun H, et al. Br J Cancer. 2024 Jul;131(2):387-402. doi: 10.1038/s41416-024-02737-0. Epub 2024 Jun 7. Br J Cancer. 2024. PMID: 38849478 - Dual role of the peptide-loading complex as proofreader and limiter of MHC-I presentation.
Brunnberg J, Barends M, Frühschulz S, Winter C, Battin C, de Wet B, Cole DK, Steinberger P, Tampé R. Brunnberg J, et al. Proc Natl Acad Sci U S A. 2024 May 28;121(22):e2321600121. doi: 10.1073/pnas.2321600121. Epub 2024 May 21. Proc Natl Acad Sci U S A. 2024. PMID: 38771881 Free PMC article. - Evaluating deep learning-based melanoma classification using immunohistochemistry and routine histology: A three center study.
Wies C, Schneider L, Haggenmüller S, Bucher TC, Hobelsberger S, Heppt MV, Ferrara G, Krieghoff-Henning EI, Brinker TJ. Wies C, et al. PLoS One. 2024 Jan 19;19(1):e0297146. doi: 10.1371/journal.pone.0297146. eCollection 2024. PLoS One. 2024. PMID: 38241314 Free PMC article. - Inhibition of p90 ribosomal S6 kinases disrupts melanoma cell growth and immune evasion.
Kosnopfel C, Wendlinger S, Niessner H, Siewert J, Sinnberg T, Hofmann A, Wohlfarth J, Schrama D, Berthold M, Siedel C, Sauer B, Jayanthan A, Lenz G, Dunn SE, Schilling B, Schittek B. Kosnopfel C, et al. J Exp Clin Cancer Res. 2023 Jul 19;42(1):175. doi: 10.1186/s13046-023-02755-5. J Exp Clin Cancer Res. 2023. PMID: 37464364 Free PMC article. - The landscape of T cell antigens for cancer immunotherapy.
Peri A, Salomon N, Wolf Y, Kreiter S, Diken M, Samuels Y. Peri A, et al. Nat Cancer. 2023 Jul;4(7):937-954. doi: 10.1038/s43018-023-00588-x. Epub 2023 Jul 6. Nat Cancer. 2023. PMID: 37415076 Review.
References
- J Exp Med. 1992 Nov 1;176(5):1453-7 - PubMed
- J Exp Med. 1988 Dec 1;168(6):2183-91 - PubMed
- J Immunol. 1993 Apr 1;150(7):2955-63 - PubMed
- J Exp Med. 1993 Apr 1;177(4):989-98 - PubMed
- J Immunol. 1993 Aug 1;151(3):1410-8 - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous